Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
| Revenue (TTM) | $1.17M |
| Gross Profit (TTM) | $-55.56M |
| EBITDA | $-85.98M |
| Operating Margin | -7603.00% |
| Return on Equity | -43.70% |
| Return on Assets | -24.90% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $4.42 |
| Price-to-Book | 2.50 |
| Price-to-Sales (TTM) | 576.11 |
| EV/Revenue | - |
| EV/EBITDA | -3.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 18.80% |
| Shares Outstanding | $55.53M |
| Float | $52.41M |
| % Insiders | 3.53% |
| % Institutions | 47.56% |
Volatility is currently contracting
The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON).
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational neuroscience R&D company, today announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure's worldwide development and commercial rights to Privosegtor. This acquisition will result in the termination of Oculis' existing license agreement with Accure, including associated milestone payments and royalties for each successful indication. This strategic transaction would enable Oculis to better harness Privosegtor's potential value going forward, without the encumbrance of the legacy license agreement with Accure, while retaining greater economic upside for the asset's future success as the Company continues to drive Privosegtor's development and pursue potential expansion opportunities.
Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.59 per share a year ago.
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the second quarter ended June 30, 2026, and provided an overview of the Company's progress.
ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) pre-IND feedback regarding Privosegtor's clinical development plan in acute multiple sclerosis (MS) relapses.
British outsourcer Mitie has agreed to be acquired by rival OCS Group International for a total value of £3.1 billion ($4.17 billion), the companies said on Tuesday.
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OCS and any ticker you trade — then tracks every position and per-strategy win rate.
